Alembic Pharmaceuticals receives USFDA final approval for Dapsone Gel 5%

What Alembic Pharmaceuticals announced

Alembic Pharmaceuticals Limited disclosed on 26 June 2026 that it has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) covering Dapsone Gel, 5%. The approval confirms that the product meets USFDA standards for safety, efficacy and quality, and is therapeutically equivalent to the reference listed drug (RLD) – Aczone Gel, 5% marketed by Almirall, LLC. The company submitted the announcement to both the Bombay Stock Exchange (BSE) and the National Stock Exchange of India (NSE) under Regulation 30 (LODR).

Alembic Pharmaceuticals receives USFDA Final Approval for Dapsone Gel, 5%.

The press release attached to the filing states that Dapsone Gel is indicated for the topical treatment of acne vulgaris. No commercial launch dates, pricing, or revenue forecasts were disclosed in the filing.

Details of the USFDA approval

• Product: Dapsone Gel, 5% (topical formulation).
• Indication: Acne vulgaris.
• Reference Listed Drug (RLD): Aczone Gel, 5% (Almirall, LLC).
• Regulatory pathway: ANDA – an abbreviated application that demonstrates bio‑equivalence to an already‑approved drug, allowing the generic product to be marketed in the United States.
• Approval status: Final approval, meaning the product can be marketed in the US pending any post‑approval requirements.
• Cumulative approvals: With this addition, Alembic now holds 244 USFDA ANDA approvals – 224 final approvals and 20 tentative approvals, underscoring its long‑standing presence in the US generic market.

The filing does not mention any conditions, post‑marketing commitments, or timelines for commercial launch. It also does not disclose any financial impact, such as expected sales or cost of goods.

About Alembic Pharmaceuticals Limited

Alembic Pharmaceuticals Limited, incorporated in 1907, is a vertically integrated research‑and‑development pharmaceutical company headquartered in Vadodara, Gujarat. The firm manufactures and markets a broad portfolio of generic and branded medicines across therapeutic areas, serving markets in India and more than 70 countries worldwide. Its state‑of‑the‑art facilities are approved by multiple global regulators, including the USFDA, UK MHRA and European authorities.

Key company highlights from the filing:

• Field force: Over 5,500 sales representatives across India.
• Regulatory track record: 244 USFDA ANDA approvals to date, reflecting a robust pipeline and strong compliance capabilities.
• Market positioning: Recognised as a leader in branded generics in India, with a diversified product mix that includes cardiovascular, anti‑infective, and dermatology segments.

The Dapsone Gel approval adds a dermatology product to Alembic’s US portfolio, complementing its existing generic offerings.

Key facts at a glance

Why this matters for investors

The USFDA approval is a regulatory milestone that expands Alembic’s product footprint in the United States, a market that contributes a meaningful share of revenue for many Indian generic manufacturers. While the filing does not quantify the commercial upside, the addition of a dermatology product could diversify Alembic’s US sales mix, which has historically been weighted toward cardiovascular and anti‑infective generics.

From a capital‑structure perspective, the announcement does not involve any issuance of shares, debt instruments, or other securities, and therefore does not dilute existing shareholders. The filing also does not indicate any pending shareholder votes or board resolutions, suggesting that the approval is a standalone regulatory event.

Investors should note that the financial impact remains undisclosed; any revenue contribution will depend on market launch strategy, pricing, and competition from other generic manufacturers of dapsone gel. Nonetheless, the cumulative ANDA count of 244 reinforces Alembic’s proven ability to navigate US regulatory pathways, which can be a competitive advantage in future product development.

Conclusion

Alembic Pharmaceuticals Limited has secured USFDA final approval for its Dapsone Gel 5% formulation, bringing its total USFDA ANDA approvals to 244. The approval adds a new dermatology product to its US portfolio but does not entail any immediate financial disclosures or changes to share capital. The filing, made on 26 June 2026, reflects a continued focus on expanding the company’s presence in regulated markets, while leaving the commercial rollout and revenue implications to be detailed in future communications.